Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.10
BASI's Cash to Debt is ranked lower than
93% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. BASI: 0.10 )
Ranked among companies with meaningful Cash to Debt only.
BASI' s 10-Year Cash to Debt Range
Min: 0.02   Max: N/A
Current: 0.1

Equity to Asset 0.43
BASI's Equity to Asset is ranked lower than
73% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. BASI: 0.43 )
Ranked among companies with meaningful Equity to Asset only.
BASI' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.83
Current: 0.43

0.31
0.83
Interest Coverage 0.68
BASI's Interest Coverage is ranked lower than
98% of the 92 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 801.71 vs. BASI: 0.68 )
Ranked among companies with meaningful Interest Coverage only.
BASI' s 10-Year Interest Coverage Range
Min: 0.24   Max: 11
Current: 0.68

0.24
11
F-Score: 6
Z-Score: 0.86
M-Score: -2.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -0.26
BASI's Operating margin (%) is ranked lower than
52% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.30 vs. BASI: -0.26 )
Ranked among companies with meaningful Operating margin (%) only.
BASI' s 10-Year Operating margin (%) Range
Min: -20.16   Max: 13.81
Current: -0.26

-20.16
13.81
Net-margin (%) 0.60
BASI's Net-margin (%) is ranked higher than
53% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.43 vs. BASI: 0.60 )
Ranked among companies with meaningful Net-margin (%) only.
BASI' s 10-Year Net-margin (%) Range
Min: -22.39   Max: 6.99
Current: 0.6

-22.39
6.99
ROE (%) 1.47
BASI's ROE (%) is ranked higher than
53% of the 162 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. BASI: 1.47 )
Ranked among companies with meaningful ROE (%) only.
BASI' s 10-Year ROE (%) Range
Min: -55.71   Max: 18.44
Current: 1.47

-55.71
18.44
ROA (%) 0.60
BASI's ROA (%) is ranked higher than
54% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.19 vs. BASI: 0.60 )
Ranked among companies with meaningful ROA (%) only.
BASI' s 10-Year ROA (%) Range
Min: -21.3   Max: 7.42
Current: 0.6

-21.3
7.42
ROC (Joel Greenblatt) (%) -0.40
BASI's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.66 vs. BASI: -0.40 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BASI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -29.14   Max: 15.89
Current: -0.4

-29.14
15.89
Revenue Growth (3Y)(%) -19.20
BASI's Revenue Growth (3Y)(%) is ranked lower than
82% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. BASI: -19.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BASI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -23.3   Max: 15
Current: -19.2

-23.3
15
EBITDA Growth (3Y)(%) -47.90
BASI's EBITDA Growth (3Y)(%) is ranked lower than
91% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. BASI: -47.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BASI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -61.2   Max: 119.8
Current: -47.9

-61.2
119.8
» BASI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

BASI Guru Trades in Q4 2013

Jim Simons 16,800 sh (-20.38%)
» More
Q1 2014

BASI Guru Trades in Q1 2014

Jim Simons 12,500 sh (-25.60%)
» More
Q2 2014

BASI Guru Trades in Q2 2014

Jim Simons Sold Out
» More
Q1 2015

BASI Guru Trades in Q1 2015

Jim Simons 10,400 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with BASI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
PE(NRI) 199.00
BASI's PE(NRI) is ranked lower than
94% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 33.80 vs. BASI: 199.00 )
Ranked among companies with meaningful PE(NRI) only.
BASI' s 10-Year PE(NRI) Range
Min: 3.05   Max: 569
Current: 199

3.05
569
P/B 1.90
BASI's P/B is ranked higher than
70% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. BASI: 1.90 )
Ranked among companies with meaningful P/B only.
BASI' s 10-Year P/B Range
Min: 0.23   Max: 3.23
Current: 1.9

0.23
3.23
P/S 0.70
BASI's P/S is ranked higher than
90% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. BASI: 0.70 )
Ranked among companies with meaningful P/S only.
BASI' s 10-Year P/S Range
Min: 0.1   Max: 1.29
Current: 0.7

0.1
1.29
PFCF 30.00
BASI's PFCF is ranked lower than
81% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. BASI: 30.00 )
Ranked among companies with meaningful PFCF only.
BASI' s 10-Year PFCF Range
Min: 1.39   Max: 113.8
Current: 30

1.39
113.8
POCF 15.31
BASI's POCF is ranked higher than
66% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.74 vs. BASI: 15.31 )
Ranked among companies with meaningful POCF only.
BASI' s 10-Year POCF Range
Min: 1.25   Max: 142.86
Current: 15.31

1.25
142.86
Current Ratio 0.73
BASI's Current Ratio is ranked lower than
95% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. BASI: 0.73 )
Ranked among companies with meaningful Current Ratio only.
BASI' s 10-Year Current Ratio Range
Min: 0.35   Max: 3.95
Current: 0.73

0.35
3.95
Quick Ratio 0.54
BASI's Quick Ratio is ranked lower than
95% of the 169 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. BASI: 0.54 )
Ranked among companies with meaningful Quick Ratio only.
BASI' s 10-Year Quick Ratio Range
Min: 0.24   Max: 3.05
Current: 0.54

0.24
3.05
Days Inventory 35.10
BASI's Days Inventory is ranked higher than
69% of the 135 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 72.34 vs. BASI: 35.10 )
Ranked among companies with meaningful Days Inventory only.
BASI' s 10-Year Days Inventory Range
Min: 22.9   Max: 91.25
Current: 35.1

22.9
91.25
Days Sales Outstanding 46.02
BASI's Days Sales Outstanding is ranked higher than
73% of the 150 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. BASI: 46.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
BASI' s 10-Year Days Sales Outstanding Range
Min: 37.96   Max: 112.17
Current: 46.02

37.96
112.17

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 2.20
BASI's Price/Tangible Book is ranked higher than
76% of the 138 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. BASI: 2.20 )
Ranked among companies with meaningful Price/Tangible Book only.
BASI' s 10-Year Price/Tangible Book Range
Min: 0.33   Max: 3.34
Current: 2.2

0.33
3.34
Price/DCF (Projected) 1.10
BASI's Price/DCF (Projected) is ranked higher than
85% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. BASI: 1.10 )
Ranked among companies with meaningful Price/DCF (Projected) only.
BASI' s 10-Year Price/DCF (Projected) Range
Min: 0.28   Max: 63
Current: 1.1

0.28
63
Price/Median PS Value 1.40
BASI's Price/Median PS Value is ranked lower than
84% of the 146 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. BASI: 1.40 )
Ranked among companies with meaningful Price/Median PS Value only.
BASI' s 10-Year Price/Median PS Value Range
Min: 0.24   Max: 3.57
Current: 1.4

0.24
3.57
Price/Graham Number 3.10
BASI's Price/Graham Number is ranked lower than
78% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. BASI: 3.10 )
Ranked among companies with meaningful Price/Graham Number only.
BASI' s 10-Year Price/Graham Number Range
Min: 0.32   Max: 6.56
Current: 3.1

0.32
6.56
Earnings Yield (Greenblatt) -0.30
BASI's Earnings Yield (Greenblatt) is ranked lower than
62% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. BASI: -0.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
BASI' s 10-Year Earnings Yield (Greenblatt) Range
Min: -0.3   Max: 10
Current: -0.3

-0.3
10
Forward Rate of Return (Yacktman) 0.24
BASI's Forward Rate of Return (Yacktman) is ranked lower than
76% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.51 vs. BASI: 0.24 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) only.
BASI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -10.2   Max: 34.5
Current: 0.24

-10.2
34.5

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:BS5.Germany,
Bioanalytical Systems Inc is a corporation organized in Indiana in 1974. The Company is a contract research organization providing drug discovery and development services and analytical instruments. Its clients and partners include pharmaceutical, biotechnology, academic and government organizations. It supports the preclinical and clinical development needs of researchers and clinicians for small molecule and large biomolecule drug candidates. The Companys principal clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic research from small start-up biotechnology companies to many of the largest global pharmaceutical companies. The drug discovery and development process is heavily regulated by the FDA and its Center for Drug Evaluation and Research. It operates in two business segments contract research services and research products, both of which address the bioanalytical, preclinical, and clinical research needs of drug developers. The contract research services segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance and quality control testing. The services provided by its contract research services segment include Product Characterization, Method Development and Validation, Bioanalytical Testing, Stability Testing, In Vivo Pharmacology, and Preclinical and Pathology Services. The products business targets life science research and designs, develops, manufactures and markets Analytical Products, In vivo Sampling Products, Vetronics Products. It promotes its services through concentrated business development efforts, scientist-to-scientist communications and centralized corporate marketing programs. The Company competes with in-house research, development, quality control and other support service departments of pharmaceutical and biotechnology companies. Its competitors include Covance, Inc., Pharmaceutical Product Development, Inc., Charles River Laboratories, Inc., Quintiles Transnational Holdings, Inc. The Company is subject to various regulatory requirements designed to ensure the quality and integrity of its data and products.
» More Articles for BASI

Headlines

Articles On GuruFocus.com
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 09 2011 
Bioanalytical Systems Inc. Reports Operating Results (10-Q/A) May 20 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) May 17 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 16 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-K/A) Feb 10 2010 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Aug 12 2009 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) May 18 2009 
Bioanalytical Systems Inc. Reports Operating Results (10-Q) Feb 23 2009 

More From Other Websites
BIOANALYTICAL SYSTEMS INC Financials May 22 2015
10-Q for Bioanalytical Systems, Inc. May 17 2015
BIOANALYTICAL SYSTEMS INC Files SEC form 10-Q, Quarterly Report May 15 2015
BASi Reports Second Quarter Results May 14 2015
Q2 2015 Bioanalytical Systems Inc Earnings Release - Before Market Open May 14 2015
Bioanalytical Systems to Release Second Quarter Fiscal 2015 Results on Thursday, May 14, 2015;... May 07 2015
Bioanalytical Systems to Release Second Quarter Fiscal 2015 Results on Thursday, May 14, 2015;... May 04 2015
Nasdaq stocks posting largest volume increases Apr 29 2015
NanoViricides Provides an Update on Its Progress over the Last Quarter Apr 06 2015
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Mar 18 2015
BASi Names Philip A. Downing Vice President of Preclinical Services Mar 17 2015
Latest updates on Biotechnology Companies: Special Research on Arrowhead, Bioanalytical Systems,... Feb 20 2015
BIOANALYTICAL SYSTEMS INC Files SEC form 10-Q, Quarterly Report Feb 17 2015
Bioanalytical Systems' Breakeven Q1 Earnings, Down Y/Y - Analyst Blog Feb 13 2015
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 12 2015
BASi Reports First Quarter Results Feb 12 2015
BASi Expands Scientific Expertise with the Hiring of Srini Jayaraman, Ph.D., Principal Investigator... Feb 11 2015
Bioanalytical Systems to Release First Quarter Fiscal 2015 Results on Thursday, February 12, 2015;... Feb 04 2015
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Feb 04 2015
BIOANALYTICAL SYSTEMS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 20 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK